Principal Financial Group Inc. Boosts Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Principal Financial Group Inc. lifted its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 3.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 123,453 shares of the company’s stock after purchasing an additional 3,727 shares during the quarter. Principal Financial Group Inc. owned about 0.43% of Krystal Biotech worth $19,340,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Creative Planning raised its position in Krystal Biotech by 64.9% during the 3rd quarter. Creative Planning now owns 5,744 shares of the company’s stock worth $1,046,000 after buying an additional 2,260 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after purchasing an additional 412 shares during the last quarter. Mount Yale Investment Advisors LLC acquired a new position in Krystal Biotech during the third quarter valued at $187,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Krystal Biotech by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,039 shares of the company’s stock valued at $184,000 after purchasing an additional 186 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Krystal Biotech by 64.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,526 shares of the company’s stock worth $1,006,000 after purchasing an additional 2,172 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of KRYS stock opened at $186.89 on Tuesday. Krystal Biotech, Inc. has a 1-year low of $125.85 and a 1-year high of $219.34. The company has a market cap of $5.38 billion, a price-to-earnings ratio of 62.51 and a beta of 0.84. The stock has a 50 day simple moving average of $157.85 and a 200-day simple moving average of $175.26.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. During the same period in the prior year, the business posted $0.30 earnings per share. The firm’s revenue for the quarter was up 116.4% on a year-over-year basis. Analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on KRYS shares. Chardan Capital boosted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $210.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).